Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of subcutaneous PL 3994 for the treatment of acute decompensated heart failure.

Trial Profile

Phase II trial of subcutaneous PL 3994 for the treatment of acute decompensated heart failure.

Planning
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs PL 3994 (Primary)
  • Indications Decompensated heart failure
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Palatin Technologies
  • Most Recent Events

    • 13 Nov 2018 Planned initiation date changed from 1 Jan 2016 to 1 Jan 2019, as per Palatin media release.
    • 13 Nov 2018 According to a Palatin Technologies media release, this Phase 2a, open label study in heart failure patients with preserved ejection fraction is targeted to commence in the first half of 2019
    • 28 Sep 2015 Planned initiation date changed from 1 Jun 2015 to 1 Jan 2016, as per Palatin media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top